STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

CRGI Discloses 6.55M IDEAYA Shares; Passive Schedule 13G Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Capital Research Global Investors reports beneficial ownership of 6,552,691 shares of IDEAYA Biosciences common stock, representing 7.5% of the 87,581,963 shares the filing states are outstanding. The disclosure is made on a Schedule 13G and includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

The filing shows CRGI has sole voting and sole dispositive power over the reported shares and names SMALLCAP World Fund, Inc. as an account on whose behalf shares are held. No group affiliation or intent to seek control is indicated in the statement.

Positive

  • Reports beneficial ownership of 6,552,691 shares of IDEAYA common stock, a clearly stated holding amount
  • Disclosed stake represents a measurable 7.5% of outstanding shares, indicating significant institutional interest
  • Filed on Schedule 13G and includes a certification that shares are held in the ordinary course of business and not to change control

Negative

  • None.

Insights

TL;DR: CRGI discloses a material passive stake in IDEAYA equal to 7.5%, signaling a notable institutional position without a stated control intent.

The filing documents a meaningful institutional holding of 6,552,691 shares (7.5%) in IDEAYA reported on Schedule 13G. Because the filer certifies the holdings are held in the ordinary course and not to influence control, this is a passive disclosure rather than an activist or control-seeking move. For investors, the development is notable as it increases institutional ownership concentration but does not by itself imply strategic change at the company.

TL;DR: Schedule 13G filing reflects passive ownership with sole voting/dispositive power but contains no indication of coordination or governance action.

The Schedule 13G shows CRGI exercises sole voting and dispositive power over the reported shares. The certification language and absence of group identification or 13D-level disclosures suggest no intent to alter board control or pursue governance actions. From a governance perspective, the filing should be viewed as increased passive institutional ownership rather than a triggering event for control-related disclosures.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Capital Research Global Investors
Signature:Jae Won Chung
Name/Title:Vice President and Senior Counsel II, Capital Research and Management Company
Date:08/05/2025

FAQ

How many IDEAYA (IDYA) shares does Capital Research Global Investors report owning?

The filing reports 6,552,691 shares of IDEAYA common stock are beneficially owned by Capital Research Global Investors.

What percentage of IDEAYA does CRGI's holding represent?

The reported ownership equals 7.5% of the 87,581,963 shares the filing states are outstanding.

Does CRGI have voting or dispositive power over the reported shares?

Yes. The filing states CRGI has sole voting power of 6,552,691 shares and sole dispositive power of 6,552,691 shares; shared powers are reported as 0.

Is this a Schedule 13G or 13D filing and what does that mean?

This is a Schedule 13G filing and it includes a certification that the securities were acquired and are held in the ordinary course of business and not to change or influence control.

On whose behalf are some shares held according to the filing?

The filing identifies SMALLCAP World Fund, Inc. as an account on behalf of which shares are held.
Ideaya Biosciences

NASDAQ:IDYA

IDYA Rankings

IDYA Latest News

IDYA Latest SEC Filings

IDYA Stock Data

3.01B
86.87M
0.91%
115.11%
11.51%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO